223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature

Prostate cancer (PC) is the most common male cancer and one of the leading causes of cancer-related morbidity and death. PC affects predominantly the elderly, the highest incidence rates being between the age of 70 and 80 years. Owing in part to the aging population and long natural history of the disease, approximately 54% of men who die of PC are older than 80 years of age. In the natural history of the disease, approximately 10% of patients will develop a castrationresistant prostate cancer (CRPC) which is characterized by a poor prognosis, with a median survival of 2 years. In a recent analysis on PC frequency in the elderly population, it has been shown that older patients are more likely to present with very advanced disease and to have a greater risk of death from PC than other competing causes.